Triple versus dual antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using Korean National Health Insurance Claim Database

被引：0
|
作者：
Noh, Yoojin [1 ]
Lee, Jimin [1 ]
Shin, Sooyoung [1 ]
Lee, Sukhyang [1 ]
机构：
[1] Ajou Univ, Coll Pharm, Suwon 441749, South Korea
来源：
PHARMACOTHERAPY | 2015年 / 35卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
344
引用
收藏
页码：E260 / E260
页数：1
相关论文
共 50 条
  • [41] Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial
    Li, Jingen
    Ju, Jianqing
    Chen, Zhuo
    Liu, Jing
    Lu, Fang
    Gao, Rui
    Xu, Hao
    TRIALS, 2018, 19
  • [42] Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trial
    Park, Soohyung
    Rha, Seung-Woon
    Choi, Byoung Geol
    Kim, Woohyeun
    Choi, Woong Gil
    Lee, Seung Jin
    Lee, Jae Beom
    Park, Ji Young
    Park, Sang Min
    Jeong, Myung Ho
    Kim, Yong Hoon
    Her, Ae-Young
    Kim, Min Woong
    Chen, Kang-Yin
    Kim, Bae Keun
    Shin, Eun-Seok
    Seo, Jae-Bin
    Ahn, Jihun
    Choi, Se Yeon
    Byun, Jae Kyeong
    Cha, Jin Ah
    Hyun, Su Jin
    Choi, Cheol Ung
    Park, Chang Gyu
    AMERICAN HEART JOURNAL, 2023, 265 : 11 - 21
  • [43] Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function A one-center retrospective cohort study
    Dang, Wenxi
    Wang, Jiajia
    Zhang, Qing
    Liu, Nairong
    Li, Wenting
    Yao, Zhuhua
    MEDICINE, 2021, 100 (16) : E25601
  • [44] Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk - A Prospective Cohort Study (PENDULUM mono Study) -
    Nakamura, Masato
    Morino, Yoshihiro
    Kakuta, Tsunekazu
    Hata, Yoshiki
    Takamisawa, Itaru
    Tanabe, Kengo
    Anzai, Hitoshi
    Takahashi, Akihiko
    Kadota, Kazushige
    Suzuki, Hiroshi
    Wakatsuki, Tetsuzo
    Okayama, Hideki
    Yamashita, Jun
    Akasaka, Takashi
    Yokoi, Hiroyoshi
    Nakagami, Takuo
    Higuchi, Yoshiharu
    Yamaguchi, Junichi
    Kimura, Takumi
    Harada, Atsushi
    Kuroda, Takeshi
    Takita, Atsushi
    Iijima, Raisuke
    Murakami, Yoshitaka
    Saito, Shigeru
    CIRCULATION JOURNAL, 2021, 85 (01) : 27 - +
  • [45] Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study)
    Redfors, Bjorn
    Ben-Yehuda, Qri
    Lin, Sheng-Hsuan
    Furer, Ariel
    Kirtane, Ajay J.
    Witzenbichler, Bernhard
    Weisz, Giora
    Stuckey, Thomas D.
    Maehara, Akiko
    Genereux, Philippe
    Giustino, Gennaro
    Rinaldi, Michael J.
    Neumann, Franz-Josef
    Metzger, D. Christopher
    Henry, Timothy D.
    Cox, David A.
    Duffy, Peter L.
    Mazzaferri, Ernest L., Jr.
    Ayele, Girma Minalu
    Mehran, Roxana
    Mintz, Gary S.
    Stone, Gregg W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (06): : 917 - 923
  • [46] Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)
    Ribera, Aida
    Ferreira-Gonzalez, Ignacio
    Ramon Marsal, Josep
    Oristrell, Gerard
    Teresa Faixedas, Maria
    Rosas, Alba
    Tizon-Marcos, Helena
    Rojas, Sergio
    Labata, Carlos
    Cardenas, Merida
    Homs, Silvia
    Tomas-Querol, Carlos
    Garcia-Picart, Joan
    Gomez-Hospital, Joan A.
    Ignacio Pijoan, Jose
    Masotti, Monica
    Mauri, Josepa
    Garcia Dorado, David
    Carvajal, C.
    Martinez, P.
    Lidon, R. M.
    Baneras, J.
    Garcia-Picart, J.
    Massotti, M.
    Jimenez, G.
    Hernandez, M.
    Regueiro, A.
    Basaganyas, J.
    Loma, P.
    Cardenas, M.
    Badosa, E.
    Fageda, A.
    Ariza, A.
    Garcia-Amigo, C.
    Cequier, A.
    Marin, G.
    Maristany, J.
    Montoya, V.
    Labata, C.
    Mauri, J.
    Fernandez-Nofrerias, E.
    Carrillo, X.
    Garcia-Garcia, C.
    Oliete, C.
    Bardaji, A.
    Bonet-Pineda, G.
    Rojas, S.
    Munoz, Juan F.
    Padilla, F.
    Homs, S.
    BMJ OPEN, 2019, 9 (07):
  • [47] Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study
    Jackson, Larry R.
    Ju, Christine
    Zettler, Marjorie
    Messenger, John C.
    Cohen, David J.
    Stone, Gregg W.
    Baker, Brian A.
    Effron, Mark
    Peterson, Eric D.
    Wang, Tracy Y.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (14) : 1880 - 1889
  • [48] The Author's Response: Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
    Kim, Dong-Yeon
    Hahn, Joo-Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (22)
  • [49] An up-dated meta-analysis of major adverse cardiac events on triple versus dual antiplatelet therapy after percutaneous coronary intervention in patients with type 2 diabetes mellitus
    Liu, Mao
    Lu, Wenjing
    Chen, Ling
    Wang, Yanmei
    Zhao, Zhuoling
    Zhang, Mei
    Du, Weiwei
    Lv, Zhan
    DATA IN BRIEF, 2018, 20 : 448 - 453
  • [50] Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
    Ning, Chen
    Ling, Fang
    Liu, Deyi
    Zhi, Zhang
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01)
12345